mRNA-delivered Alb-IL-2var variant prolongs exposure, boosts CD8+ T cells, and enhances antitumor immunity
Messenger RNA delivery of a dual CD25/CD122 affinity-tuned IL-2 variant prolongs exposure and potentiates antitumor T cell immunity.
Background
Traditional interleukin-2 (IL-2) cancer therapies face significant challenges due to systemic toxicity, poor pharmacokinetics, and unintended activation of regulatory T (Treg) cells, which can suppress anti-tumor immunity. These issues limit its therapeutic potential despite IL-2's critical role in activating CD8+ effector T cells. A key gap is the inability to selectively stimulate effector T cells while avoiding Treg activation, which is often mediated via the IL-2Rα (CD25) subunit. This research addresses this by engineering an IL-2 variant with modified receptor binding.
